TherapeuticsMD
TXMD
168 hedge funds and large institutions have $467M invested in TherapeuticsMD in 2019 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 57 increasing their positions, 39 reducing their positions, and 13 closing their positions.
138% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 13
46% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 39
39% more call options, than puts
Call options by funds: $3.33M | Put options by funds: $2.4M
12% more funds holding
Funds holding: 150 → 168 (+18)
0.01% less ownership
Funds ownership: 1.43% → 1.42% (-0.01%)
26% less capital invested
Capital invested by funds: $627M → $467M (-$160M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$11.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.3M |
| 3 |
DM
Deerfield Management
New York
|
+$6.47M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.68M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$5.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$6.8M |
| 2 |
Public Employees Retirement Association of Colorado
Denver,
Colorado
|
-$4.58M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.71M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$2.18M |
| 5 |
SMH
Sanders Morris Harris
Houston,
Texas
|
-$1.83M |
TXMD Hedge Fund Activity: Q4 2019 in Review
168 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q4 2019, worth a combined $467M — down 26% from $627M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TXMD positions and 13 closed out — a net gain of 18 holders — while 57 added to existing stakes and 39 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $11.9M. The largest seller was Bank of New York Mellon, cutting an estimated $6.8M.
- 168 institutional investors held TherapeuticsMD (TXMD) as of Q4 2019, up from 150 in Q3 2019.
- Funds reported $467M of TherapeuticsMD stock for Q4 2019, down 26% quarter-over-quarter.
- 31 funds opened new TherapeuticsMD positions in Q4 2019 and 13 closed out, a net change of +18 holders.
- The largest TherapeuticsMD buyer in Q4 2019 was Rubric Capital Management (New York), an estimated $11.9M added.
- The largest TherapeuticsMD seller in Q4 2019 was Bank of New York Mellon, an estimated $6.8M sold.
Based on aggregated 13F filings for Q4 2019.